# Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update
Canonical URL: https://biopharmsignal.com/news/LQDA/liquidia-corporation-announces-preliminary-full-year-2025-yutrepia-net-sales-and-corporate-update
Ticker: LQDA
Company: Liquidia Corporation
Source: Liquidia Corporation
Published: 2026-01-09 11:30 EST
Original Source URL: https://www.liquidia.com
## Summary

Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025

## Article Body
Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025 Received more than 2,800 unique patient prescriptions since launch in June 2025 Generated more than $30 million of positive cash flow during the fourth quarter 2025
## Recent Company News
- 2026-05-27 12:30 EST — [Liquidia Corporation to Present at 2026 Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-present-at-2026-jefferies-global-healthcare-conference) — Source: Liquidia Corporation
- 2026-05-11 10:30 EST — [Liquidia Corporation Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-first-quarter-2026-financial-results) — Source: Liquidia Corporation
- 2026-05-06 12:30 EST — [Liquidia Corporation to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-participate-in-upcoming-investor-conferences) — Source: Liquidia Corporation
- 2026-05-04 12:30 EST — [Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026](https://biopharmsignal.com/news/LQDA/liquidia-corporation-to-report-first-quarter-2026-financial-results-on-may-11-2026) — Source: Liquidia Corporation
- 2026-03-05 11:30 EST — [Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LQDA/liquidia-corporation-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-update) — Source: Liquidia Corporation
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)